An ongoing phase I/II trial aimed at treating metastatic melanoma patients with tumour-infiltrating lymphocytes transduced with CXCR2, followed by high dose IL-2 has clinical outcome reports pending (NCT01740557). The gene discussed is IL2; the disease is neoplasm.